|Bid||31.96 x 45100|
|Ask||31.98 x 39400|
|Day's Range||31.96 - 32.03|
|52 Week Range||31.96 - 33.16|
|PE Ratio (TTM)||N/A|
|YTD Daily Total Return||-1.06%|
|Beta (5Y Monthly)||0.77|
|Expense Ratio (net)||0.06%|
In this article we talked about Cathie Wood’s recent comments about money supply, inflation, interest rates, bitcoin and present Wood’s top 10 small-cap stock picks. Click to skip ahead our lengthy discussion and see Cathie Wood’s Top 5 Small-Cap Stock Picks. “The year has certainly started off in a wild way.” ARK Investment Management’s CEO, […]
The big shareholder groups in Compugen Ltd. ( NASDAQ:CGEN ) have power over the company. Generally speaking, as a...
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today progress from its ongoing license agreement with AstraZeneca (LSE: AZN) (STO: AZN) (NASDAQ: AZN) under which the program has achieved a preclinical milestone. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bispecific and multi-specific antibody products based on one of Compugen's pipeline programs, with AstraZeneca responsible for all research, development and commercial activities. In connection with this first milestone, Compugen is entitled to receive a $2 million payment from AstraZeneca.